These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 7627963

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.
    Hall DG, Stoica G.
    J Bone Miner Res; 1994 Feb; 9(2):221-30. PubMed ID: 8140935
    [Abstract] [Full Text] [Related]

  • 4. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P.
    Cancer Res; 2008 Nov 01; 68(21):8945-53. PubMed ID: 18974139
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.
    El-Abdaimi K, Ste-Marie LG, Papavasiliou V, Dion N, Cardinal PE, Huang D, Kremer R.
    Int J Oncol; 2003 Apr 01; 22(4):883-90. PubMed ID: 12632083
    [Abstract] [Full Text] [Related]

  • 7. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P.
    Cancer Res; 2007 Oct 15; 67(20):9894-902. PubMed ID: 17942921
    [Abstract] [Full Text] [Related]

  • 8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 9. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Löwik C.
    J Bone Miner Res; 2001 Jun 01; 16(6):1077-91. PubMed ID: 11393785
    [Abstract] [Full Text] [Related]

  • 10. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G.
    Cancer Res; 2007 Sep 15; 67(18):8742-51. PubMed ID: 17875715
    [Abstract] [Full Text] [Related]

  • 13. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R.
    J Bone Miner Res; 2001 Aug 15; 16(8):1486-95. PubMed ID: 11499871
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR.
    J Clin Invest; 1997 May 15; 99(10):2509-17. PubMed ID: 9153295
    [Abstract] [Full Text] [Related]

  • 15. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
    Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T.
    Cancer Res; 2006 Feb 15; 66(4):2067-73. PubMed ID: 16489006
    [Abstract] [Full Text] [Related]

  • 16. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.
    van der Pluijm G, Que I, Sijmons B, Buijs JT, Löwik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG.
    Cancer Res; 2005 Sep 01; 65(17):7682-90. PubMed ID: 16140935
    [Abstract] [Full Text] [Related]

  • 17. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
    van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos SE.
    Breast Cancer Res Treat; 2009 Nov 01; 118(2):307-13. PubMed ID: 18989771
    [Abstract] [Full Text] [Related]

  • 18. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T.
    Int J Cancer; 1998 Jul 17; 77(2):279-85. PubMed ID: 9650565
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ, Mancini I.
    Support Care Cancer; 2002 Jul 17; 10(5):399-407. PubMed ID: 12136223
    [Abstract] [Full Text] [Related]

  • 20. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ.
    Cancer Res; 2001 Jun 01; 61(11):4432-6. PubMed ID: 11389072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.